That is going to remain the case Doc and I don’t see automation lowering the cost such that it’s not ever an issue. However, the current standard of care ends quite rapidly and then patients basically go on to a death sentence. There are other treatments that are in fact more expensive than DCVax-L that do not provide substantial benefit comparatively in terms of survival.
As I mentioned, I’ve reviewed things quite carefully, and though I do think LP will be working diligently to keep costs low and lower then if possible with automation, approval does not require automation, nor would approval for costs at current levels or even, given updated information with regard to adding poly-iclc, at a substantially higher possible price even in the UK. The savings in terms of survival and quality of life would be so substantial and the monthly costs literally many times lower than existing treatments that are questionable in terms of benefits.
Market Data 
Markets 
AI
